Almirall Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting

[In The News]

EXTON, Pa., Feb. 5, 2019 /PRNewswire/ -- Almirall, S.A. (ALM), today announced that an abstract reporting the results from two Phase III studies of KX2-391 Ointment in the treatment of actinic keratosis has been accepted for presentation at the Late-Breaking Research Program at the 2019...

View the full article